Lumenis sells its surgery division to Boston-Global

The Israeli medical device company Lumenis will sell its surgical division to the global device giant Boston Scientific (NYSE: BSX) for $ 1.07 billion. Part of the proceeds will be invested in the growth of Lumenis’ aesthetic division and eye division. Boston will leave the company’s operations in the country, and this will be integrated into its urology division. Completion of the transaction is subject to regulatory approvals.

Lumenis is one of the leading companies in the field of energy-based medical devices, and is engaged in manufacturing and development. These are intended for surgical, aesthetic treatments and those in the field of eyes and vision. The company markets in dozens of countries around the world and employs 1,500 people, 450 of them in Israel.

The surgical division that will be sold includes laser solutions for minimally invasive surgeries in the fields of urology, ENT and more. It is Lumenis that has developed the laser technologies used in these fields. The technology developed by it has demonstrated increased clinical efficacy over other solutions and has led to a significant reduction in surgical times in the treatment of kidney and urinary tract stones and in the treatment of an enlarged prostate.

“Boston Scientific has acquired our surgical division because it knows, like the industry as a whole, that we are a leader in innovation in the field.” Said Tzipi Ozer Armon, CEO of Lumenis. “For us, this is a double achievement: we will also be able to reach many more markets on the Boston Scientific platform and make Lumenis’ unique technology accessible to tens of millions of other users around the world. “Better Technology for Better Patient Care. This is a moment of pride for Lumenis and the entire Israeli industry.”

Lumenis’ aesthetics and eye care business remains under the current controlling shareholder, the BPEA investment fund, which has entered these areas as a strategic investment that will be a growth engine for Lumenis.